Actelion shareholders hand Elliott-backed insurgents a defeat

Elliott Advisors' dramatic effort to rally investors behind a push to put Actelion up for sale ran into a brick wall today as shareholders backed management's slate of candidates for the board. A rival slate of candidates led by ex-Novartis exec James Shannon was defeated, and Actelion CEO Jean-Paul Clozel vowed to get back to the biotech's primary task: advancing new drugs through the clinic.

"So much energy was spent for this fight, which should have better gone into the development of new drugs," Clozel said, according to a report from Dow Jones. Of course, it was trouble in the clinic that inspired Elliott's effort to force a sale of the company in the first place. Last year Actelion experienced a stinging setback with the failure of its experimental sleeping pill almorexant. That was followed by further setbacks on the development front and yesterday the Swiss biotech was hit with a hefty verdict in a case revolving around its acquisition of CoTherix.

But Reuters reports that the pro-management sentiment at the annual meeting was clear early as as shareholders booed remarks made by Elliott's Dominik Dolenec.

Actelion is left with a much stronger board, though. In its struggle with Elliott the company recruited former GlaxoSmithKline CEO Jean-Pierre Garnier and former Schering-Plough CFO Robert Bertolini for its slate of candidates. They will now be on hand to help advise Actelion as it navigates troubled waters.

- read the Dow Jones report
- and here's the Reuters story

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.